INTRODUCTION
The vast community of microorganisms that exists on our epithelial surfaces is collectively termed the microbiota. The microbiome refers to the microbiota plus the surrounding environment. The microbiota is able to induce disease [1] [2] [3] and also able to regulate immunity or tolerance [4] [5] [6] [7] . An imbalance between pathogenic and protective microbes characterizes dysbiosis, a perturbation in the normal composition of commensal microbiota [8] . Examples of conditions resulting from or contributing toward dysbiosis include Clostridium difficile [1] , Crohn's disease [2, 9] , and nonalcoholic steatohepatitis (NASH) [3] . In NASH, enterohepatic portal flow enables direct transfer of microbe and immune system-derived inflammatory mediators from intestine to liver, leading to the activation of several molecular pathways. Henao-Mejia et al. [10] identified that inflammasome-deficient mice had expanded Bacteroidetes and experienced an influx of lipopolysaccharide into the portal circulation, leading to increased hepatic tumor-necrosis factor and exacerbation of the NASH phenotype. Thus, gut dysbiosis may transfer immune cells and signals to distant sites, rendering extraintestinal tissues such as organ allografts susceptible to changes in the intestinal microbiota.
In transplant patients, immunosuppression, metabolic abnormalities, and antibiotics mediate profound alterations of microbiota. This review examines this dynamic relationship at immunologic and clinical levels and presents the evidence to date describing the impact of the microbiota in renal transplantation.
STUDYING THE MICROBIOME
The thousands of species and the millions of genes expressed by the microbiota (i.e., metagenome) are a reflection of the functional diversity required to maintain microbiota homeostasis. This vast array of gene expression has been studied by many groups to identify microbiome conditions that lead to health versus disease. Genetic tools to characterize microbiota include targeted sequencing of the 16S ribosomal RNA genes and shotgun sequencing of transcribed genes [11] (Table 1) . The huge amount of information obtained can be processed using principal coordinate analyses and classical multidimensional scaling [12] . Briefly, the sequenced 16 s ribosomal RNA (rRNA) dataset is processed by phylogenetic classification to measure relative abundance of the bacterial taxa in each sample. Using extended local similarity analysis [13] and linear discriminant analysis effect size [14] , one can measure differences between samples in terms of biologic diversity and biomarker expression. The Human Microbiome Project [15] and European Meta Hit Consortium [16] have identified 99% of the genera present in normal human microgenomes in Western populations for investigators to use as a template for classifying individual samples or large populations.
MECHANISMS OF MICROBIOTA STIMULATION OF THE ENTERIC IMMUNE SYSTEM
The microbiota interacts with the intestinal epithelial cells (IEC) and resident immune cells to activate both innate and adaptive mechanisms ( Fig. 1 ). Microbial products are sensed by receptors of the IEC, such as toll-like receptor (TLR) and nucleotidebinding oligomerization domain (NOD). For example, peptidoglycan from gram-negative bacteria binds NOD1 and elicits production of CC chemokine ligand 20 and b-defensin-3 to recruit B cells to the lamina propria and induce expression of immunoglobulin A [17] . Development of intestinal lymphoid follicles depends on the presence of both microbial products and lymphoid tissue inducer cells, a subset of innate lymphoid cells (ILC), in the lamina propria [18] . At homeostasis, bacterial products stimulate production of mucus, bactericidal molecules, and biofilms by IEC to exclude pathogenic bacteria and promote colonization by commensal bacteria [19, 20] . Virulence factors may penetrate the mucus and activate innate effectors in the lamina propria such as natural killer T cells [21] and ILC. In response to IEC-derived proinflammatory cytokines, ILC release interleukin (IL)-22 to help maintain the integrity of the epithelium and produce antimicrobial peptides [22] . In contrast, commensal bacteria provide tonic stimulation of the apical receptors to dampen the inflammatory response by various adaptive mechanisms. For example, Bacteroides and Lactobacillus species inhibit activation of the classical nuclear factor kappa B pathway and its downstream proinflammatory genes [23] .
KEY POINTS
The microbiota interacts with the host in a bidirectional manner; microbes stimulate innate and adaptive mechanisms, and in turn require immunocompetence to suppress pathogenic bacteria and maintain gut homeostasis.
Gut dysbiosis may cause transfer of immune cells and signals to distant sites, rendering extraintestinal tissues such as organ allografts susceptible to changes in the intestinal microbiota.
Dysbiosis may be associated with antigen crossreactivity because of molecular mimicry, potentially affecting the response to alloantigen. Products from microbiota engage the adaptive immune system by either directly interacting with dendritic cells (DC) or inducing IEC cytokine expression that influences recruitment and differentiation of neutrophils, macrophages, or DC [24] . At homeostasis, cytokines such as IL-33, IL-25, transforming growth factor beta (TGFb), and thymic stromal lymphopoietin activate macrophages and DC. In the presence of TGFb and retinoic acid, DC promote induced regulatory T cell (Treg) (iTreg). Microbial antigens from Bacteroides fragilis and Clostridia species promote Treg development [25, 26] . Antigen-specific iTreg then migrate to lymph nodes, express anti-inflammatory cytokines such as IL-10 and TGFb, and mediate direct killing or inactivation of effector cells. In this way, iTreg suppress the immune response to commensal organisms and self-antigen at a local and systemic level.
During dysbiosis or mucosal injury, pathogenic microbial products stimulate secretion of proinflammatory cytokines (e.g., IL-6, IL-1, IL-23, and IL-12),which induce differentiation of CD4 þ T helper cell type 1 (Th1) and T helper cell type 17 (Th17) cells in the small intestine [25, 26] . Th17 differentiation is induced in the gut by Candidatus arthromitus or segmented filamentous bacteria (SFB) [27] . Th17 cells bolster the intestinal barrier via IL-22 and prevent infection from pathogenic bacteria via IL-17 and interferon gamma expression, and can thus potentially restore homeostasis in a dysbiotic environment [27] .
The balance between anti-inflammatory and proinflammatory cells can lead to either suppression or activation of disease. The ability to alternate between pathways depends on the microbes and cytokines present. For example, retinoic acid (a cofactor for both iTreg and Th17 differentiation) is suppressed in the presence of noncommensal organisms and proinflammatory cytokines, thus allowing naïve T cells to be programmed into inflammatory effectors [28] . Specific antibiotic agents have been shown to block retinoic acid suppression [4] . This demonstrates how changes in microbiota may impact changes in molecular signaling that influence one T-cell pathway over another.
Microbiota regulation of T cells has been associated with antigen-independent systemic inflammation. For example, intestinal SFB promote the development of rheumatoid arthritis via regulation of Th17 differentiation. This was shown in germ-free mice, where introduction of SFB alone could trigger arthritis via IL-17 expressed by Th17 cells [4] . These data showing how a single microbe can promote a T-cell subset to drive autoimmune disease, demonstrate how gut microbes influence systemic inflammation.
Microbiota-derived systemic inflammation may affect alloimmunity via molecular mimicry driven by antigen cross-reactivity, such as homologous sequences between Kell antigen on red blood cells and B. fragilis [29] . Pantenburg et al. [30] showed that cross-reactive, primed alloreactive T cells led to accelerated skin allograft rejection in mice infected with Leishmania major. This suggests that interactions with microbiota may alter the immune responses to alloantigen because of the presence of cross-reactive, environmentally derived antigen.
BIDIRECTIONAL RELATIONSHIP BETWEEN MICROBIOTA AND THE IMMUNE SYSTEM AFTER ALLOTRANSPLANTATION
Although the microbiota clearly influences immune pathways, dysregulated immune responses also impact the microbiome in a bidirectional manner. For example, absence of Treg in mice was associated with pronounced Th2-type inflammation in the gut and airways, as well as altered gut microbiota, suggesting that Treg maintain eubiosis in the gut by regulating Th2 inflammation [31] . Independent of cause, inflammation in the gut leads to changes in microbiota composition [32] , leading to dysbiosis. Dysbiosis in turn disrupts the immune thresholds set by 'normal' commensals, resulting in chronic, recurrent infection, or inflammation and inability to clear 'abnormal' microbiota [24] .
Host factors in transplant patients that influence this bidirectional relationship include antibiotics, immunosuppression, and chronic kidney disease (CKD). Germ-free or antibiotic-treated mice are deficient in Th17 cells [27] and have impaired Treg function [33] . These deficiencies are associated with dysregulation of immunity, inflammation, and response to infection, leading to an increased burden of pathogens and the potential to develop crossreactive alloantibodies. Thus, dysbiosis associated with chronic antibiotic use may have immune consequences in allograft recipients beyond simply the emergence of antibiotic-resistant organisms.
CKD is associated with several immunologic sequelae that can affect the microbiota (Table 2) [34]; conversely, the microbiota have been linked to clinical and immunologic changes in animal models of CKD (Table 3) , [36] [37] [38] . These data illustrate that renal failure predisposes a host to the influx of microbial metabolites, which may have profound clinical impact on these patients.
Immunosuppression is also linked to dysbiosis. T-cell depleting antibodies (antithymocyte globulin), nondepleting antibodies (basiliximab), and glucocorticoids may produce changes in microbiota [39] . These changes may affect one's ability to restore immunity after lymphodepletion, as compensatory homeostatic T-cell proliferation is partially driven by commensal bacterial antigens [47] . Although conventionally raised T-cell-deficient mice show rapid T-cell proliferation after adoptive transfer of naïve T cells, germ-free T-cell-deficient mice undergo only a slow homeostatic proliferation [48] , supporting the role of microbiota in influencing immunity in the chronically immunodeficient patient.
CLINICAL MANIFESTATIONS OF MICROBIOME DISRUPTION
Differences in microbiota after transplantation can be associated with clinically significant events. Decreased Firmicutes in small bowel recipients has been associated with acute rejection [49] . In lung transplant patients, restoration of microbiota diversity decreased the risk of bronchiolitis obliterans syndrome [50] . Bronchial samples containing greater than 10% Pseudomonas aeruginosa were associated with symptomatic infection, whereas those containing greater than 10% Pseudomonas fluorescens were not. No sample had greater than 10% of both species [51] . Such changes, however, are difficult to interpret in the presence of concomitant antimicrobial administration. ]. As mentioned above, reduced diversity of airway microbiota was associated with acute infection in lung recipients [51] .
Changes in microbiota may alter metabolism of antirejection medications [54 & ]. In a study of 19 kidney recipients who submitted rectal samples, those who required more than a 50% increase in tacrolimus dosing during the first month of transplantation were more likely to host an abundance of fecal Faecalibacterium prausnitzii in the first week posttransplant [54 & ]. Oral bioavailability of tacrolimus depends partially on intestinal cytochrome P450 3A4 (CYP3A4) and P glycoprotein function and is altered in renal transplant recipients with diarrhea [55] . Although no causal relationship has been demonstrated, it is tempting to speculate that as gut mucosal health is associated with tacrolimus metabolism, perhaps gut microbiota contribute to drug metabolism via maintenance or disruption of mucosal integrity.
THERAPEUTIC OR DIAGNOSTIC OPTIONS UNDER INVESTIGATION
Characterizing microbial shifts and biomarkers associated with rejection or infection may identify patients who would benefit from earlier intervention or surveillance. This may also assist in the development of therapeutics that modulate the immune system to promote allograft acceptance or tolerance. Recent studies have explored the use of fecal microbiota transplant (FMT), probiotics, and dietary modifications.
Diet impacts the availability of metabolites required for intestinal immune cells. For example, retinoic acid is required for Th17 development, lymphocyte migration, and DC maturation [56] [57] [58] . Colonocytes benefit from a fat-rich diet, and mice treated with such a diet have reduced colitis [59] , inflammatory bone disease, and bone erosion [60] . These mice have altered levels of gut Prevotella species as well as pro-IL-1b in neutrophils. Avoidance of certain microbe-metabolized nutrients may also help protect allograft health. In animal models, chronic dietary exposure of phosphatidylcholine, choline, or L-carnitine led to higher plasma TMAO levels in CKD patients and was directly related to progressive renal fibrosis and cardiovascular disease [35 && ,38] . Although studies in renal transplant patients are limited, these observations suggest that dietary modifications may affect not [38] Gut microbial metabolite trimethylamine-N-oxide (TMAO) directly contributes to progressive renal fibrosis and dysfunction in animal models; increases mortality risk in CKD; enhances platelet hyperreactivity and thrombosis risk; regulates lipid metabolism and inflammation; TMAO may be linked to specific dietary nutrients and gut microbes Wang et al. 2012 [39] Experimental uremia in rats increases bacterial translocation from gut, which is associated with higher serum IL-6 and C-reactive protein levels
McIntyre et al. 2011 [40] Progressive levels of circulating bacterial endotoxin and LPS with CKD are highest in patients on dialysis. LPS levels are an independent predictor of mortality only immune responses and microbiota composition but also the availability of toxic metabolites. Probiotics have been used in transplant recipients for the treatment of C. difficile. A retrospective study of lung and liver transplant recipients found Lactobacillus oral preparations to be well tolerated and effective against C. difficile infection [61] . Lactobacillus GG has shown efficacy, feasibility, and safety in preventing graft versus host disease in stem cell transplant recipients [62] , although prospective studies are lacking. Oral Lactobacillus and Bifidobacterium were associated with improved intestinal barrier function, partial gut microbial restoration, and reduced liver injury after liver transplant in rats [63, 64] . Whether probiotics affect outcomes other than C. difficile infection, and which probiotics are beneficial for renal transplant recipients, is unknown.
Restoration of microbiome diversity may be feasible through FMT. This was highly effective in patients with recurrent C. difficile colitis [65] ; however, FMT in solid organ transplant has yet to be tested. FMT for C. difficile colitis was not associated with significant complications (such as bacteremia) in nonimmunosuppressed [65] or immunosuppressed patients [66] .
Precision microbiome restoration using only a single bacterial species has recently been reported by Buffie et al [67 && ]. In a murine model, the investigators treated mice with different antibiotic regimens and identified distinct changes in microbiota composition and C. difficile susceptibility among the groups. They used a cohort of immunosuppressed, antibiotic-treated, stem cell allotransplanted humans to identify native bacteria that displayed strong inhibition against C. difficile in both humans and mice. C. scindens significantly enhanced resistance to C. difficile infection after adoptive transfer into mice, whereas transfer of other Clostridia species did not [67 && ]. Recently, FMT in a kidneyheart transplant recipient with recurrent C. difficile was associated with restored microbiota diversity, improved clinical outcome, and loss of vancomycinresistant enterococcus fecal dominance [68] .
Certainly, avoidance of broad-spectrum antibiotic use is essential to preserving microbial biodiversity and limiting development of resistance. Unfortunately, the immunosuppressed patient often requires empiric antimicrobial coverage to prevent overwhelming sepsis. Discovering ways to restore microbiota diversity or introduce essential microbial by products in this situation is thus highly desirable.
CONCLUSION
Dysbiosis in the renal transplant patient may occur as a product of several contributing circumstances, including the effects of chronic kidney disease on systemic immunity and the gut microbiome, immunosuppression regimens, exposure to alloantigen and infection, and antimicrobial therapy. Microbiota effect changes in innate molecular defense mechanisms and shape T-cell populations that can shift the immune climate toward pro or anti-inflammatory conditions. Microbiota thus represents an important point of regulation for immunomodulation in the transplant patient.
Shifts in the microbiota posttransplant have been recently identified; however, larger studies are needed to understand how microbiome alterations before and after transplantation can be used to predict clinical response to therapy, select those at risk for rejection or opportunistic infection, and design targeted therapies that promote health and graft tolerance.
